{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001249","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.978205+00:00","generated_at":"2026-05-28T10:40:40.891351+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments","bullets":["Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.","Amended employment agreements for CEO Traversa, CFO Shenouda, CAO Ence extend option exercisability upon termination.","NEOs receive no salary increases for FY2025, no cash bonuses or long-term incentive awards for FY2024.","All further retention payments for NEOs and Kelly suspended until Board approves strategic initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001249","json":"https://secwatch.observer/filing/0001213900-25-001249.json","markdown":"https://secwatch.observer/filing/0001213900-25-001249.md","text":"https://secwatch.observer/filing/0001213900-25-001249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/0001213900-25-001249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/ea0226941-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T10:40:40.891351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19a87df487","claim":"Paul Kelly was elected as Chief Operating Officer at RELMADA THERAPEUTICS, INC..","evidence_excerpt":"Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/0001213900-25-001249-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}